ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0033684 | Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. | Protein (substance)|Protein|gene product|protein|PROTEINS|proteins|PROTEIN|Protein-containing product|Proteins|Protein, NOS|Protein (NOS)|Product containing protein (product) | Proteins |
C0001271 | Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. | actin|Actin (substance)|actins|Actin | Actins |
C0025517 | Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) | Generalized metabolic disorder|METABOLIC DISORDERS|Generalised metabolic disorder|METABOLIC DISORDERS: GENERAL|metabolic diseases|metabolic disorder|Metabolism--Disorders|Metabolic disease, NOS|Metabolic disorder|Metabolic disease|Metabolic Disorders|Diseases, Metabolic|Unspecified disorder of metabolism|Disease, Metabolic|Metabolic Disease|Thesaurismoses|metabolism disorder|metabolic disorders|Metabolic Disorder|metabolic disease|MD - Metabolic disorders|Metabolic disease (disorder)|Thesaurismosis|Generalized metabolic disorder (disorder)|Metabolic derangement|Metabolic disorder, NOS | Metabolic Diseases |
C1449705 | Co-immunoprecipitation (Co-IP) is a popular technique for protein interaction discovery. In a co-IP the target antigen precipitated by the antibody "co-precipitates" a binding partner/protein complex from a lysate. It is assumed that these proteins are related to the function of the target antigen at the cellular level. | Co Immunoprecipitation|Co-Immunoprecipitation|Co-Immunoprecipitations | Co-Immunoprecipitation |
C0008844 | null | cistron|Cistrons | Cistron |
C0554181 | null | Structural engineer (occupation) | Structural engineer |
C0043375 | white crystalline sugar extracted from wood or straw; used in dyeing and tanning and in diabetic diets; also called wood sugar. | D-xylose|XYLOSE|D Xylose|Xylose (substance)|d-xylose|(+)-Xylose|Xylose|Product containing xylose (medicinal product)|Xylose-containing product|d xylose|aldehydo-D-xylose|D-Xylose|xylose|Wood sugar | xylose |
C0282109 | Catalytically active enzymes that are formed by the combination of an apoenzyme (APOENZYMES) and its appropriate cofactors and prosthetic groups. | null | Holoenzymes |
C0389995 | A group of intracellular-signaling serine threonine kinases that bind to RHO GTP-BINDING PROTEINS. They were originally found to mediate the effects of rhoA GTP-BINDING PROTEIN on the formation of STRESS FIBERS and FOCAL ADHESIONS. Rho-associated kinases have specificity for a variety of substrates including MYOSIN-LIGHT-CHAIN PHOSPHATASE and LIM KINASES. | rho Kinase|rho-Associated Kinases|Protein Kinases, ROCK|ROCK Protein Kinases|Coiled-Coil Kinase, rho-Associated|rho-Kinase|rho Associated Kinases|rho-Associated Kinase|rho Associated Kinase|rho Associated Coiled Coil Kinase|rho-Associated Coiled-Coil Kinase|ROK Kinase | rho-Associated Kinases |
C0251761 | null | null | DVP protocol |
C0251761 | null | null | DVP protocol |
C0004153 | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen. | Atheroscleroses|atherosclerotic cardiovascular disease|atherosclerosis|atheroscleroses|Atherosclerosis, NOS|ATHEROSCLEROSIS|Atheromatosis|atheromatosis|Atherosclerotic Cardiovascular Disease|Atherosclerosis|Narrowing and hardening of arteries|Atheromatosis, NOS|ATHEROSCLEROTIC VASCULAR DISEASE|Atherosclerotic cardiovascular disease|atherosclerotic vascular disease|Atherosclerosis (morphologic abnormality)|ascvd | Atherosclerosis |
C0008971 | Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. | protocol medical|Protocol, Clinical|clinical protocols|medical protocol|Protocols, Clinical|medical protocols|Clinical Protocol|clinical protocol|Clinical Protocols|Medical protocols|clinicals protocols | Clinical Protocols |
C0008971 | Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. | protocol medical|Protocol, Clinical|clinical protocols|medical protocol|Protocols, Clinical|medical protocols|Clinical Protocol|clinical protocol|Clinical Protocols|Medical protocols|clinicals protocols | Clinical Protocols |
C0368761 | Blast cells are in an immature (undifferentiated) stage in cellular development, occurring before the appearance of the definitive characteristics exhibited by fully differentiated cells. | Blast cell|blasts|Hemohistioblast|Blasts|blast cells|Hemocytoblast|blast|Blast Cell|Blast cell (cell)|Ferrata cell|Blast Cells|Polyblast|Hematohistioblast | Blast Cell |
C0242596 | Remnant of a tumor or cancer after primary, potentially curative therapy. | Residual Neoplasms|Neoplasm, Residual|Residual Minimal Diseases|Minimal Residual Disease|Residual Minimal Disease|MRD|minimal residual disease (MRD)|Detectable Residual Disease|Minimal Residual Diseases|remainder of a tumor or cancer|minimal residual disease|Residual Neoplasm|Minimal Disease, Residual|residual neoplasm|Residual Disease, Minimal | Neoplasm, Residual |
C0018939 | Disorders of the blood and blood forming tissues. | Disorder of hematopoietic system, NOS|Hematologic disease|Blood disorder, NOS|Disorder of haematopoietic system|Blood dyscrasia|Blood dyscrasia NOS|Hematologic Disorders|Disease, Hematologic|Blood Disorders|Blood Disorder|DYSCRASIA BLOOD (NOS)|Diseases, Blood|hematologic diseases|Diseases of blood and blood-forming organs|blood disorder diagnosis|hematologic disease|hematological diseases|Disease of haematopoietic system, NOS|Disease of blood AND/OR blood-forming organ (navigational concept)|Hemopoietic disease|Blood--Diseases|Disease, Hematological|blood disease|Disorder of haematopoietic system, NOS|Diseases of the blood and blood-forming organs|Haematologic disease|Disease of hematopoietic system, NOS|BLOOD DYSCRASIA|HEMATOLOGIC DISORDER|Hematopoietic system syndrome, NOS|DISEASES OF THE BLOOD AND BLOOD-FORMING ORGANS|Hematologic Disorder|blood disorders|Hematological Disorder|Diseases, Hematologic|Hemopoietic disorder|Disease of blood AND/OR blood forming organ|Haematopoietic system syndrome, NOS|blood system disorder|Disease of blood and blood forming organ, NOS|DISORDER BLOOD (NOS)|Disorder of hematopoietic system (navigational concept)|HEMATOLOGIC DISORDERS|Hematologic and Lymphocytic Disorder|Hematologic Disease|Hematopoietic system syndrome|Haematopoietic system syndrome|HEMATOLOGIC PROBLEM|Hematological Disease|Disease, Blood|Unspecified diseases of blood and blood-forming organs|blood dyscrasias|Hematologic Diseases|blood diseases|hematologic disorders|Blood dyscrasia syndrome|haematological disorders|DISORDER HEMATOLOGIC|blood dyscrasia|blood disorder|Blood disorder|Blood dyscrasia, NOS|Blood Disease|Haematologic disease, NOS|Blood Dyscrasia|Blood Diseases|General Hematopoietic System Diseases and Syndromes|DISEASES OF THE HEMATOPOIETIC AND IMMUNE SYSTEMS|hematological disorder|hematologic disorder|Hematological Diseases|Hematologic diseases|hematological disorders|Hematopoietic system disease or syndrome|Haemopoietic disease|Disorder of hematopoietic system|hematological disease|Disease of blood AND/OR blood-forming organ|HEMATOPOIETIC SYSTEM DISEASES: GENERAL TERMS|Haemopoietic disorder|HEMATOLOGIC PROBLEM, NOS|Hematologic disease, NOS|Diseases, Hematological | Hematological Disease |
C0007635 | Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. | cell culturing|Cultured Cell|Cell, Cultured|cultured cell|cells cultured|cultured cells|Cultured Cells|Cultured cells (substance)|Cultured cells|Cells, Cultured|Cell Strain | Cultured Cells |
C0005953 | The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. | hematopoietic marrow|Bone marrow, NOS|bone marrow|All bone marrow (body structure)|Bone Marrow|Bone marrow structure|Marrow, Bone|Reticuloendothelial System, Bone Marrow|Haematopoietic marrow|Bone marrow|BM - Bone marrow|Medulla ossea|Hematopoietic marrow|Medulla ossium|Bone marrow structure (body structure)|All bone marrow|BONE MARROW | Bone Marrow |
C0376545 | Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. | Haematologic neoplasm|Hematological Malignancies|Malignancy, Hematological|Neoplasms, Hematologic|Malignancies, Hematologic|Hematological Neoplasms|Blood cancer|Hematologic Cancer|Hematologic neoplasm|Hematological Neoplasm|Hematologic Malignancy|malignancies hematologic|Blood tumor|Hematologic Neoplasm|blood cancer|blood cancers|carcinoma bone marrow|Hematologic malignancy|hematologic cancer|Malignancy, Hematologic|Hematological Tumors|Neoplasms, Hematological|Malignancies, Hematological|bone marrow carcinoma|hematologic neoplasms|Neoplasm, Hematological|Hematologic neoplasm (disorder)|hematologic malignancies|hematological malignancies|Hematological Malignancy|bone carcinoma marrow|Malignant Hematologic Neoplasm|hematological malignancy|cancer blood|Neoplasm, Hematologic|Hematologic Neoplasms|Hematological neoplasm|hematologic malignancy|Haematologic malignancy|Hematological Tumor|Hematologic Malignancies | Hematologic Neoplasms |
C0082420 | Endoglin (658 aa, ~71 kDa) is encoded by the human ENG gene. This protein plays a role in transforming growth factor receptor signaling. | CD105|Transforming Growth Factor P Receptor III|ORW1|CD105 Antigen|END|ENG|HHT1|ORW|Endoglin|Endoglin (Osler-Rendu-Weber Syndrome 1) | Endoglin, human |
C0301944 | The establishment of viable, functional grafted tissue within the body of a host. | Graft acceptance (finding)|Engraftment|Reconstitution by graft|Graft acceptance|engraftment | Graft acceptance |
C0085110 | Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID). | Severe Combined Immunodeficiency Syndrome|Immunologic Deficiency, Severe Combined|SCID - Severe combined immunodeficiency|SCID|Severe Combined Immunodeficiencies|Combined Immunodeficiency, Severe|SCID, NOS|combined immunodeficiency severe|Severe combined immunodeficiency disease, NOS|Immunodeficiency, severe combined|Severe combined immunodeficiency|combined T and B cell inborn immunodeficiency|Severe Combined Immunodeficiency|Severe combined immunodeficiency (SCID)|Severe Combined Immunologic Deficiency|Combined T-cell and B-cell immunodeficiency|Immunodeficiency Syndrome, Severe Combined|Severe combined immunodeficiency disease (disorder)|Immunodeficiency, Severe Combined|Severe Combined Immune Deficiency|scid|severe combined immunodeficiency disease|IMMUNODEFICIENCY, SEVERE COMBINED|scids|Combined Immunodeficiencies, Severe|Severe combined immunodeficiency disease|Immunodeficiencies, Severe Combined|combined immunodeficiencies severe|severe combined immunodeficiency | Severe Combined Immunodeficiency |
C0280449 | An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001) | nonlymphoblastic leukemia, secondary acute|Secondary Acute Myeloid Leukemia|acute non-lymphocytic leukemia, secondary|acute nonlymphocytic leukemia, secondary|Secondary Acute Myeloblastic Leukemia|secondary acute non-lymphoblastic leukemia|non-lymphocytic leukemia, secondary acute|myeloid leukemia, secondary acute|acute non-lymphoblastic leukemia, secondary|acute nonlymphoblastic leukemia, secondary|acute myeloid leukemia, secondary|secondary ANLL|secondary acute nonlymphocytic leukemia|Secondary Acute Myelocytic Leukemia|secondary AML|secondary acute non-lymphocytic leukemia|secondary acute myelogenous leukemia|Secondary Acute Myelogenous Leukemia|Secondary Acute Granulocytic Leukemia|nonlymphocytic leukemia, secondary acute|Secondary AML|non-lymphoblastic leukemia, secondary acute|secondary acute nonlymphoblastic leukemia|myelogenous leukemia, secondary acute|Secondary Acute Myeloid Leukemia (AML)|secondary acute myeloid leukemia|Secondary AGL|acute myelogenous leukemia, secondary | Secondary Acute Myeloid Leukemia |
C0023467 | Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. | Nonlymphocytic Leukemias, Acute|acute nonlymphocytic leukemia|Leukemias, Acute Nonlymphoblastic|Acute myeloblastic leukaemia|Leukemia, Acute Myeloid|Leukemias, Acute Myeloblastic|Leukemia, Myeloid, Acute|Myeloblastic Leukemia, Acute|Myeloid leukemia, acute|Myeloblastic Leukemias, Acute|Myelocytic Leukemia, Acute|LEUKEMIA, ACUTE MYELOGENOUS|ANLL|Leukemia, Myelocytic, Acute|Leukemia, Acute Nonlymphocytic|Leukemias, Acute Nonlymphocytic|LEUKEMIA, MYELOCYTIC, ACUTE|Acute myeloid leukemia, disease|acute granulocytic leukemia|AML - Acute myeloblastic leukemia|Acute myeloid leukemia, disease (disorder)|Acute Myelogenous Leukemias|Acute Myeloid Leukemia, NOS|Acute myeloid leukaemia - category|Leukemia, Myelogenous, Acute|Acute myelogenous leukaemia|acute myeloblastic leukemia|ACUTE MYELOGENOUS LEUKEMIA|Acute Myeloblastic Leukemia|Acute non-lymphocytic leukemia|Acute Myeloid Leukemia Not Otherwise Specified|Leukemia, acute myeloid|Leukemias, Acute Myelocytic|Acute Nonlymphoblastic Leukemias|AML|Acute myelocytic leukaemia|Acute Nonlymphocytic Leukemias|Acute granulocytic leukemia|Leukemia, Nonlymphoblastic, Acute|AML - Acute myeloid leukemia|Acute Nonlymphoblastic Leukemia|aml|acute leukemias non lymphoblastic|Acute myeloid leukemia, no ICD-O subtype|Acute Myeloid Leukemias|Acute non-lymphocytic leukaemia|acute nonlymphocytic leukemia (ANLL)|leukemia, acute nonlymphocytic|Nonlymphoblastic Leukemia, Acute|anll|Myeloid Leukemias, Acute|acute non-lymphoblastic leukemia|acute myelocytic leukemia|Acute Myeloid Leukemia NOS|LEUKEMIA ACUTE MYELOBLASTIC|Leukemia, Acute Nonlymphoblastic|Myelocytic Leukemias, Acute|Myelogenous Leukemias, Acute|Acute Myeloid Leukemia Not Otherwise Categorized|Leukemia, Acute Myeloblastic|Acute myelocytic leukemia|LEUKEMIA MYELOBLASTIC ACUTE|Myelogenous Leukemia, Acute|Acute Myelogenous Leukemia|Acute myeloid leukemia, no International Classification of Diseases for Oncology subtype|acute myelocytic leukaemia|LEUKEMIA, MYELOID, ACUTE|Acute Myeloid Leukemia|Acute Myelocytic Leukemia|acute myeloid leukaemia|Myeloid Leukemia, Acute|Acute Nonlymphocytic Leukemia|non-lymphoblastic leukemia acute|Acute myeloid leukaemia|leukemia, acute myeloid|Acute myeloid leukemia|Leukemia, Acute Myelogenous|LEUKEMIA, ACUTE MYELOID|Acute Myeloblastic Leukemias|acute myeloid leukemias|Acute Granulocytic Leukemia|AML - Acute myeloblastic leukaemia|Hematopoeitic - Acute Myleogenous Leukemia (AML)|Nonlymphoblastic Leukemias, Acute|acute myelogenous leukemia (AML)|acute myelogenous leukemia|LEUKEMIA, MYELOGENOUS, ACUTE|Acute myeloid leukaemia, disease|acute myelogenous leukaemia|Leukemias, Acute Myeloid|AML, NOS|ACUTE MYELOBLASTIC LEUKEMIA|Leukemia, Myeloblastic, Acute|Acute granulocytic leukaemia|acute non-lymphocytic leukemia|Acute myeloid leukemia, NOS|Acute Myelocytic Leukemias|Acute Myeloid Leukemia (AML)|AML - Acute myeloid leukaemia|LEUKEMIA, GRANULOCYTIC, ACUTE|Acute myelogenous leukemia (AML)|Acute myeloid leukemia - category (morphologic abnormality)|Acute myeloid leukaemia, no ICD-O subtype|Leukemias, Acute Myelogenous|Acute myeloid leukemia, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Acute myeloblastic leukemia|acute myeloid leukemia|LEUKEMIA, MYELOBLASTIC, ACUTE|AML - Acute Myeloid Leukemia|acute nonlymphoblastic leukemia|Leukemia, Acute Myelocytic|acute myelogenous leukemias|Leukemia, Nonlymphocytic, Acute|Acute myelogenous leukemia|Acute myeloid leukemia - category|Nonlymphocytic Leukemia, Acute | Leukemia, Myelocytic, Acute |
C0023453 | An antiquated term that refers to acute lymphoblastic leukemia with large and irregular lymphoblasts. | Lymphoblastic leukemia, NOS, L2 type|Acute lymphoblastic leukaemia, L2 type|Acute lymphoid leukemia, L2 type|L2 Lymphocytic Leukemia|Lymphoblastic Leukemia, Acute, Adult|Lymphoblastic Leukemia, Acute, L2|Lymphocytic Leukemia, L2|Lymphoblastic leukaemia, L2 type|Leukemia, Lymphocytic, Acute, L2|Leukemia, L2 Lymphocytic|Acute lymphoid leukaemia, L2 type|Acute lymphocytic leukaemia, L2 type|Acute lymphatic leukemia, L2 type|FAB L2|Acute lymphatic leukaemia, L2 type|Acute lymphoblastic leukemia, L2 type|L2 Acute Lymphoblastic Leukemia|Lymphoblastic leukemia, L2 type|Leukemia, Lymphoblastic, Acute, L2|Lymphoblastic leukaemia, NOS, L2 type|Acute lymphocytic leukemia, L2 type|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | L2 Acute Lymphoblastic Leukemia |
C0026764 | A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. | multiple myeloma (MM)|multiple myelomas|MULTIPLE MYELOMA|myeloma, multiple|plasma cell neoplasm|Cell Myelomas, Plasma|Myeloma-Multiple|kahler disease|MYELOMA, MULTIPLE|myelomatosis|MYELOMA|multiple myeloma|myelomas|Kahler disease|Plasma-cell Myeloma|MYELOMATOSIS MULTIPLE|Plasma-Cell Myelomas|Plasmacytic myeloma|Myeloma|Multiple myeloma (clinical)|MULTIPLE MYELOMA MYELOMATOSIS|plasma cell myeloma|Plasma Cell Myeloma|Myeloma, Plasma-Cell|myeloma, plasma cell|multiple myelomatosis|myeloma|Myeloma, Plasma Cell|Multiple Myelomas|Myelomas, Multiple|Myeloma Multiple|Multiple myeloma (disorder)|Multiple Myeloma|Plasma-Cell Myeloma|Myelomas, Plasma-Cell|kahler's disease|Multiple myeloma, no International Classification of Diseases for Oncology subtype|Disease, Kahler|Plasma-cell myeloma|Multiple myeloma / Plasma cell neoplasm|Myeloma-Multiples|Myelomatoses|PLASMA CELL MYELOMA|Cell Myeloma, Plasma|Kahler's disease|multiple myeloma and other plasma cell neoplasms|Multiple myeloma|KAHLER-BOZZOLO DISEASE|Plasma cell myeloma|neoplasm, plasma cell|Myeloma, NOS|MYELOMA, PLASMA CELL, MALIGNANT|Plasma Cell Myelomas|KAHLER DISEASE|Multiple myeloma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Myeloma, Multiple|Multiple myeloma, no ICD-O subtype|Myelomatosis|Multiple Myeloma/Plasma Cell Myeloma|Myelomas, Plasma Cell|plasma cell neoplasms|Kahler Disease | Multiple Myeloma |
C0039736 | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. | THALIDOMIDE|Sedalis|Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-|Alpha-Phthalimidoglutarimide|(+-)-Thalidomide|Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-|Product containing thalidomide (medicinal product)|2, 6-Dioxo-3-phthalimidopiperidine|(±)-thalidomide|Thalidomide-containing product|alpha-phthalimidoglutarimide|Thalidomide|1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-|N-phthaloylglutamimide|α-N-phthalylglutaramide|2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione|(±)-N-(2,6-dioxo-3-piperidyl)phthalimide|N-phthalylglutamic acid imide|(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide|N-(2,6-dioxo-3-piperidyl)phthalimide|N-Phthalylglutamic acid imide|thalidomide|N-Phthalyl-glutaminsaeure-imid|2,6-Dioxo-3-phthalimidopiperidine|THAL|2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione|alpha-(N-Phthalimido)glutarimide|2,6-dioxo-3-phthalimidopiperidine|N-Phthaloylglutamimide|N-(2,6-Dioxo-3-piperidyl)phthalimide|(+)-Thalidomide|α-phthalimidoglutarimide|alpha-N-Phthalylglutaramide|Thalidomide (substance)|N-Phthalylglutamic Acid Imide|(-)-Thalidomide|α-(N-phthalimido)glutarimide|1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline|3-Phthalimidoglutarimide|3-phthalimidoglutarimide|Thalidomidum|.alpha.-Phthalimidoglutarimide|Talidomida | thalidomide |
C0597357 | A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. | protein receptor|receptor protein|Receptor|protein receptors|Receptor (substance)|receptors|Receptors|receptor|proteins receptor|Receptor Protein|receptor proteins | receptor |
C0039736 | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. | THALIDOMIDE|Sedalis|Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-|Alpha-Phthalimidoglutarimide|(+-)-Thalidomide|Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-|Product containing thalidomide (medicinal product)|2, 6-Dioxo-3-phthalimidopiperidine|(±)-thalidomide|Thalidomide-containing product|alpha-phthalimidoglutarimide|Thalidomide|1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-|N-phthaloylglutamimide|α-N-phthalylglutaramide|2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione|(±)-N-(2,6-dioxo-3-piperidyl)phthalimide|N-phthalylglutamic acid imide|(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide|N-(2,6-dioxo-3-piperidyl)phthalimide|N-Phthalylglutamic acid imide|thalidomide|N-Phthalyl-glutaminsaeure-imid|2,6-Dioxo-3-phthalimidopiperidine|THAL|2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione|alpha-(N-Phthalimido)glutarimide|2,6-dioxo-3-phthalimidopiperidine|N-Phthaloylglutamimide|N-(2,6-Dioxo-3-piperidyl)phthalimide|(+)-Thalidomide|α-phthalimidoglutarimide|alpha-N-Phthalylglutaramide|Thalidomide (substance)|N-Phthalylglutamic Acid Imide|(-)-Thalidomide|α-(N-phthalimido)glutarimide|1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline|3-Phthalimidoglutarimide|3-phthalimidoglutarimide|Thalidomidum|.alpha.-Phthalimidoglutarimide|Talidomida | thalidomide |
C0014762 | Immature, nucleated ERYTHROCYTES occupying the stage of ERYTHROPOIESIS that follows formation of ERYTHROID PRECURSOR CELLS and precedes formation of RETICULOCYTES. The normal series is called normoblasts. Cells called MEGALOBLASTS are a pathologic series of erythroblasts. | erythroblasts|normoblast|Erythroblasts|Nucleated red blood cell - observation|Nucleated erythrocyte, NOS|Nucleated erythrocyte|NUCLEATED RED BLOOD CELLS|Erythroblast (cell)|Nucleated RBC|Nucleated red cell|Nucleated Red Cell|Nucleated red blood cell (cell)|Erythroblast|NRBC - Nucleated red blood cell present|Nucleated Red Blood Cell|Erythrocytes, Nucleated|Nucleated Erythrocyte|nucleated erythrocytes|NUCLEATED RED CELLS|Nucleated red cell, NOS|Nucleated red cells|Nucleated Erythrocytes|Normoblast|Nucleated red blood cell, NOS|Nucleated red blood cell|nucleated red blood cells|erythroblast|nucleated red cells|Erythrocyte, Nucleated|Nucleated Red Blood Cells|normoblasts|Nucleated Red Cells | Erythroblasts |
C0014819 | The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction. | Erythrocyte production, function (observable entity)|Erythrocyte production|Erythrocyte Differentiation|erythrocyte cell differentiation|Erythrocyte production, function|erythropoiesis|Erythropoieses|erythropoieses|Erythrocyte production, NOS|erythrocyte production|erythrocyte differentiation|red blood cell differentiation|Erythropoiesis, NOS|RBC differentiation|Erythropoiesis | Erythropoiesis |
C0023473 | Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. | chronic granulocytic leukaemia|Leukemia, Chronic Myelogenous|Myelogenous Leukemias, Ph1-Positive|CHRONIC MYELOCYTIC LEUKEMIA|Myeloid Leukemia, Ph1 Positive|LEUKEMIA CHRONIC MYELOCYTIC|granulocytic leukemia, chronic|CML - Chronic myeloid leukaemia|Leukemias, Chronic Myeloid|Leukemia, Ph1-Positive Myeloid|Leukemia, Philadelphia-Positive Myeloid|CML - Chronic myeloid leukemia|Myelogenous Leukemias, Chronic|Ph1-Positive Myeloid Leukemia|Leukemia, Chronic Myelocytic|Leukemia, Myelogenous, Chronic|LEUKEMIA MYELOCYTIC CHRONIC|Chronic myelogenous leukemia|Myelogenous Leukemia, Ph1 Positive|Myeloid Leukemia, Chronic|chronic myeloid leukemia|Chronic Granulocytic Leukemias|Myeloid Leukemias, Ph1-Positive|CML|Chronic myelocytic leukemia|Chronic Myeloid Leukemias|leukemia, chronic myelogenous|CGL|Chronic granulocytic leukemia|Leukemia, Chronic Myeloid|Leukemias, Chronic Granulocytic|Myelocytic Leukemias, Chronic|Chronic Granulocytic Leukemia|chronic myelocytic leukemia|Myeloid Leukemias, Philadelphia-Positive|Leukemia, Myelogenous, Ph1 Positive|Myeloid leukemia, chronic|Myeloid Leukemia, Philadelphia Positive|chronic myelogenous leukemia|Myeloid Leukemia, Philadelphia-Positive|Leukemias, Ph1-Positive Myeloid|Leukemia, Ph1-Positive Myelogenous|Granulocytic Leukemias, Chronic|Ph1-Positive Myelogenous Leukemias|Ph1-Positive Myeloid Leukemias|chronic myelogenous leukaemia|myelogenous leukemia, chronic|Chronic myelogenous leukaemia|Chronic myeloid leukaemia|cml|Chronic Myelogenous Leukemia|CHRONIC GRANULOCYTIC LEUKEMIA|Philadelphia-Positive Myeloid Leukemias|Leukemia, Myelogenous, Ph1-Positive|Leukemia, Myeloid, Ph1-Positive|Hematopoeitic - Chronic Myelocytic Leukemia (CML)|Chronic myelosis|Chronic myelogenous leukemia, no International Classification of Diseases for Oncology subtype|Myelosis|Leukemia, Myeloid, Philadelphia Positive|CGL - Chronic granulocytic leukemia|chronic granulocytic leukemia|Leukemia, Myeloid, Chronic|Chronic Myelocytic Leukemia|Leukemia, Myeloid, Philadelphia-Positive|BCR-ABL Positive Chronic Myelogenous Leukemia|LEUKEMIA, CHRONIC MYELOID|CML - Chronic Myelogenous Leukemia|LEUKEMIA, MYELOCYTIC, CHRONIC|Chronic Myelocytic Leukemias|Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Myeloid Leukemia, Ph1-Positive|Myelogenous Leukemia, Chronic|Leukemias, Philadelphia-Positive Myeloid|LEUKEMIA, CHRONIC MYELOGENOUS|Chronic Myelogenous Leukemias|Chronic myelogenous leukemia, no ICD-O subtype|CGL - Chronic granulocytic leukaemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Leukemia, Chronic Granulocytic|Chronic Myelogenous Leukemia (CML)|Chronic myelogenous leukemia (CML)|chronic myeloid leukemias|LEUKEMIA, MYELOID, CHRONIC|Leukemia, Granulocytic, Chronic|Chronic myeloid leukaemia, disease|myelocytic leukemia, chronic|Leukemias, Chronic Myelogenous|Leukemia, myelomonocytic (Naegeli)|Myelocytic Leukemia, Chronic|LEUKEMIA, GRANULOCYTIC, CHRONIC|Chronic granulocytic leukaemia|Myeloid Leukemias, Chronic|chronic myeloid leukaemia|Leukemia, Myelocytic, Chronic|Chronic myeloid leukemia, disease (disorder)|Leukemias, Ph1-Positive Myelogenous|Ph1-Positive Myelogenous Leukemia|Chronic myeloid leukemia, disease|Granulocytic Leukemia, Chronic|Myelogenous Leukemia, Ph1-Positive|Chronic Myeloid Leukemia|Leukemia, Myeloid, Ph1 Positive|Chronic myelocytic leukaemia|chronic myelogenous leukemia (CML)|Leukemias, Chronic Myelocytic|LEUKEMIA, MYELOGENOUS, CHRONIC|Chronic myeloid leukemia|Philadelphia-Positive Myeloid Leukemia|Chronic myelogenous leukemia, no International Classification of Diseases for Oncology subtype (morphologic abnormality) | Myeloid Leukemia, Chronic |
C0086024 | complex nucleotide produced by certain bacteria consisting of a porphyrin like corrin ring cooordinated with a cobalt ion, a phosphoribose, and a 5,6-dimethylbenzimidazole base. | COBALAMIN|Cobalamin|cobalamins|cobalamin|Cobalamin (substance)|Cobalamins|Cobalamin preparation, NOS | cobalamins |
C0065844 | null | Mecobalamina|mecobalamin|methylvitamin B12|Mecobalaminum|Methyl(III)cobalamin|Methylcobalamin-containing product|Methylcobalamin (substance)|METHYLCOBALAMIN|methylcobalamine|Co-methylcobalamin|Product containing methylcobalamin (medicinal product)|Methylcobalamin|cobinamide, Co-methyl deriv., hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole|methylcobalamin|CH3-B12|MeCbl|Methyl vitamin B12|Mecobalamin | mecobalamin |
C0018133 | The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. | Graft Versus Host Diseases|Homologous Wasting Disease|graft-versus-host disease|homologous wasting disease|Graft versus host disease|Graft-vs-Host disease|disease graft host vs|Runt disease|Graft-versus-host disease|GVHD - Graft-versus-host disease|graft versus host disease|Graft versus host disease, NOS|Graft-vs-Host Diseases|Graft-Versus-Host Disease|gvhd|autoimmune foreign transplant disease|gvh disease|Graft-versus-host disease (disorder)|host versus graft disease|Runt Disease|host vs graft disease|disease graft host versus|Graft-Versus-Host-Disease|graft vs host disease|Disease, Graft-Versus-Host|Runting syndrome|Graft Versus Host Disease|GRAFT VERSUS HOST DISEASE|gvh|runt disease|Graft Vs. Host Disease|GVHD|GvHD|Graft-Versus-Host Diseases|Disease, Runt|Graft vs Host Disease|Graft-versus-host disease, unspecified|Graft-vs-Host Disease|Diseases, Graft-Versus-Host|disease graft versus host|graft-versus-host diseases|graft-vs-host disease|Diseases, Graft-vs-Host|Disease, Graft-vs-Host|GVH|Disease, Homologous Wasting | Graft-vs-Host Disease |
C0085692 | Inflammation of the bladder resulting in bloody urine. | CYSTITIS HEMORRHAGIC|Hemorrhagic Cystitis|haemorrhagic cystitis|Hemorrhagic cystitis|HEMORRHAGIC CYSTITIS|Haemorrhagic cystitis|hemorrhagic cystitis|CYSTITIS HAEMORRHAGIC|Hemorrhagic cystitis (disorder)|cystitis hemorrhagic | Hemorrhagic cystitis |
C0206373 | A process in which peripheral blood is exposed in an extracorporeal flow system to photoactivated 8-methoxypsoralen (METHOXSALEN) and ultraviolet light - a procedure known as PUVA THERAPY. Photopheresis is at present a standard therapy for advanced cutaneous T-cell lymphoma; it shows promise in the treatment of autoimmune diseases. | extracorporeal photopheresis|Extracorporeal photopheresis (procedure)|Extracorporeal Photochemotherapy|Extracorporeal photopheresis|Photochemotherapies, Extracorporeal|Photopheresis, Extracorporeal|extracorporeal photochemotherapy|Extracorporeal Photochemotherapies|extracorporeal photophoresis|Extracorporeal Photopheresis|Photochemotherapy, Extracorporeal|photopheresis|Photophoresis|Therapeutic photopheresis|Extracorporeal Photophoresis|Extracorporeal photochemotherapy | Photopheresis |
C1511567 | null | null | Cutaneous Involvement |
C1333717 | This gene is involved in transcriptional initiation. | General Transcription Factor IIA, 2, 12kDa Gene|GTF2A2 gene|TFIIA gamma subunit|GTF2A2|HsT18745|general transcription factor IIA subunit 2|TRANSCRIPTION FACTOR IIA, 2|TFIIA|GTF2A2 Gene|GENERAL TRANSCRIPTION FACTOR IIA, GAMMA SUBUNIT|TF2A2 | GTF2A2 gene |
C1333717 | This gene is involved in transcriptional initiation. | General Transcription Factor IIA, 2, 12kDa Gene|GTF2A2 gene|TFIIA gamma subunit|GTF2A2|HsT18745|general transcription factor IIA subunit 2|TRANSCRIPTION FACTOR IIA, 2|TFIIA|GTF2A2 Gene|GENERAL TRANSCRIPTION FACTOR IIA, GAMMA SUBUNIT|TF2A2 | GTF2A2 gene |
C0026987 | A partial or complete replacement of the bone marrow stroma by fibrous tissue. It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003 | MMM|MYELOFIBROSIS WITH MYELOID METAPLASIA|Myelosclerosis|chronic idiopathic myelofibrosis|Myelofibrosis|Myelofibrosis (disorder)|MYELOFIBROSIS|bone marrow fibrosis|mos|myelofibrosis|Myelofibrosis, NOS|Myelosclerosis, NOS|MF - Myelofibrosis|bone fibrosis marrow|fibrosis bone marrow|myelosclerosis|Myelofibrosis NOS | Myelofibrosis |
C1533699 | A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate. | Gemtuzumab ozogamicin (substance)|Gemtuzumab ozogamicin-containing product|GEMTUZUMAB OZOGAMICIN|Gemtuzumab-Ozogamicin|gemtuzumab ozogamicin|hP67.6-Calicheamicin|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin|Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody|Product containing gemtuzumab ozogamicin (medicinal product) | gemtuzumab ozogamicin |
C0010711 | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|1.beta.-D-Arabinofuranosylcytosine|2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-|Cytosine-beta-arabinoside|2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-|Arabinosylcytosine|Cytosine arabinoside|Cytarabinum|cytarabinum|4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|Cytosine-.beta.-arabinoside|Citarabina|arabinofuranosylcytosine|Cytosine Arabinoside|1-.beta.-D-Arabinofuranosylcytosine|Cytarabine|1-beta-D-Arabinofuranosylcytosine|aracytidine|Arabinofuranosylcytosine|Cytosine-1-beta-D-arabinofuranoside|Beta-cytosine Arabinoside|cytosine arabinoside|Arabinoside, Cytosine|Beta-Cytosine Arabinoside|2(1H)-pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-|1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone|Product containing cytarabine (medicinal product)|cytosine-.beta.-arabinoside|Cytarabine-containing product|cytarabine|1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone|beta-cytosine arabinoside|CYTARABINE|arabinosylcytosine|1.beta.-D-arabinofuranosylcytosine|Cytarabine (substance)|Aracytidine|1-beta-D-arabinofuranosylcytosine|1-Beta-D-arabinofuranosylcytosine|cytosine-β-D-arabinofuranoside|1-.beta.-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone|2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-|.beta.-Cytosine arabinoside | cytarabine |
C1293131 | Procedure to cause two adjacent structures to be structurally joined together | fusion procedure|Fusion|Fusion procedure (procedure)|fusions|Fusion procedure|fusion | Fusion procedure |
C0017287 | The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development. | Rearrangement, DNA|Gene re-arrangement, NOS|Gene re-arrangement|Gene Rearrangement|Rearrangements, DNA|Rearrangement, Gene|DNA rearrangement|Gene rearrangement|DNA Rearrangements|GENE RE-ARRANGEMENTS|Gene re-arrangement (finding)|Gene rearrangement (substance)|gene rearrangement|Gene Rearrangements|Rearrangements, Gene|DNA Rearrangement | Gene Rearrangement |
C0393022 | A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. | rituximab|Rituximab|Product containing rituximab (medicinal product)|Rituximab-containing product|Rituximab CD20 Antibody|Rituximab (substance)|CD20 Antibody, Rituximab|RITUXIMAB|C2B8 Monoclonal Antibody|riTUXimab|Chimeric Anti-CD20 Antibody|Rituximab ABBS | rituximab |
C0220654 | Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation. | Leptomeningeal Carcinomatosis|Carcinomatous Meningitis|Meningeal carcinomatosis|CANCER, MENINGEAL CARCINOMATOSIS|Carcinomatosis, Leptomeningeal|Meningitides, Carcinomatous|Meningitis, Carcinomatous|metastases meningeal|Malignant meningitis|Malignant meningitis (disorder)|leptomeningitis, carcinomatous|Leptomeningeal Carcinomatoses|neoplastic meningitis|Carcinomatosis of the Meninges|Carcinomatoses, Meningeal|Meningeal Carcinomatoses|Carcinomatous Meningitides|BRAIN TUMOR, MENINGEAL CARCINOMATOSIS|Meningeal Carcinomatosis|Carcinomatous meningitis|carcinomatous meningitis|MENINGEAL CARCINOMATOSIS|malignant meningitis|INTRACRANIAL NEOPLASM, MENINGEAL CARCINOMATOSIS|carcinomatous leptomeningitis|leukemic meningitis|lymphomatous meningitis|meningeal carcinomatosis|Carcinomatoses, Leptomeningeal|Carcinomatosis, Meningeal | Meningeal Carcinomatosis |
C0376596 | MONOSACCHARIDES and DISACCHARIDES present in food, such as those present in fruits and vegetables and milk products, or those added to food such as DIETARY SUCROSE (table sugar) or HIGH FRUCTOSE CORN SYRUP. | Sugars, Dietary|dietary sugar|Sugar, Dietary|Dietary Sugar | Dietary Sugars |
C0376596 | MONOSACCHARIDES and DISACCHARIDES present in food, such as those present in fruits and vegetables and milk products, or those added to food such as DIETARY SUCROSE (table sugar) or HIGH FRUCTOSE CORN SYRUP. | Sugars, Dietary|dietary sugar|Sugar, Dietary|Dietary Sugar | Dietary Sugars |
C0031831 | Individuals licensed to practice medicine. | Physicians|physician|doctor|doctors|RoleClassPhysician|PHYSICIAN|medical doctor|physicians|medical doctors|Medical doctor (occupation)|DR|Medical doctor|Doctor|Medical Doctors|MEDICAL DOCTORS|Physician (occupation)|Physician | Physicians |
C0007587 | The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. | death cell|Cell Death|cells death|necrocytosis|cell death|Cell Death Process|Death, Cell | Cell Death |
C0162638 | A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically-programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. | apoptose|apoptotic programmed cell death|Mechanism that allows cells to self-destruct when it is necessary|PCD|RCD|apoptotic process|programmed cell death|Apoptosis (morphologic abnormality)|type I programmed cell death|Classical Apoptosis|Apoptosis, Classical|self destruction of the cell|Cell Death, Programmed|Apoptosis|Apoptotic Process|APOPTOSIS|apoptotic cell death|Programmed Cell Death|Gene-directed cell death|Classic Apoptoses|Apoptosis, Classic|Classic Apoptosis|apoptosis|Programmed Cell Death, Type I|programmed cell death by apoptosis | Apoptosis |
C0007097 | A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." | Epithelial tumor, malignant|epithelial carcinoma|Malignant Epithelial Neoplasm|Malignant epithelial neoplasm|Malignant Epithelial Neoplasms|carcinoma|Carcinoma, no subtype|CARCINOMA|carcinomas|Carcinoma|Tumor, Malignant Epithelial|Epithelial Neoplasms, Malignant|Epitheliomas|Neoplasms, Malignant Epithelial|Malignant Epithelial Tumor|Epithelial tumour, malignant|epitheliomas|Malignant Epithelial Tumors|Epithelial Tumors, Malignant|Epithelioma Malignant|CARCINOMA, MALIGNANT|Other Carcinoma|Carcinomas|Epithelioma|Malignant epithelial tumour|Epithelial Tumor, Malignant|Epithelial Neoplasm, Malignant|Malignant Epithelioma|Epithelial Carcinoma|Malignant epithelial neoplasm (disorder)|Carcinoma, no subtype (morphologic abnormality)|Malignant epithelial tumor|Carcinoma, NOS|Neoplasm, Malignant Epithelial|epithelioma | Carcinoma |
C0017429 | The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs. | Human genome|Human Genomes|human genome|Human Genome|Genomes, Human|human genomes|genome human|Human genome (substance) | Genome, Human |
C0079427 | Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. | oncosuppressor gene|Tumor suppressor gene|Tumor Suppressing Genes|genes suppressor tumour|Gene, Tumor Suppressor|Recessive Oncogenes|antioncogene|Gene, Cancer Suppressor|Oncogene, Recessive|Tumor Suppressing Gene|Tumor Suppressor Gene|tumor suppressors|Emerogenes|Tumor Suppressor Genes|Oncogenes, Recessive|Suppressor Gene, Cancer|Tumor Suppressors|Recessive Oncogene|Tumour suppressor gene|Anti-Oncogenes|Gene, Onco-Suppressor|tumor suppressing gene|Emerogene|Antioncogene|Genes, Cancer Suppressor|Cancer Suppressor Gene|tumour suppressor gene|Anti-Oncogene|Gene, Tumor Suppressing|emerogene|Suppressor Genes, Cancer|Onco-Suppressor Genes|Tumor Suppressor|genes tumor suppressor|genes suppressor tumor|suppressor genes cancer|Anti Oncogenes|Antioncogenes|Onco-Suppressor Gene|recessive oncogenes|Genes, Tumor Suppressing|Antioncogene (substance)|Genes, Onco Suppressor|anti-oncogenes|tumor suppressor genes|tumor suppressor|Anti-oncogene|tumor suppressor gene|cancer suppressor gene|Genes, Tumor Suppressor|recessive oncogene|suppressor tumor|Cancer Suppressor Genes|Genes, Onco-Suppressor | Tumor Suppressor Genes |
C0007586 | The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. | Cycles, Cell Division|Division Cycles, Cell|Cycles, Cell|cell cycle division|cell division cycle|Cycle, Cell|Cell Cycles|cycle cell|cell-division cycle|Cell Division Cycles|Cell Cycle|Cycle, Cell Division|cell cycle|Division Cycle, Cell|Cell Cycle Pathway|Cell cycle|cells cycle|Cell Division Cycle | Cell Cycle |
C0029016 | Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. | Oncogene (substance)|Transforming Gene|cancer-causing gene|cancer gene|Transforming Genes|Oncogenes|Genes, Transforming|Gene, Transforming|Cancer-Promoting Gene|oncogene|cancer genes|oncogenes [cancer-causing gene]|oncogenes|Oncogene | Oncogenes |
C1510411 | In medicine, the change that a normal cell undergoes as it becomes malignant. | Transformation|Cell Transformation|Transformed|transformation|Transforming|Cellular Transformation | metaplastic cell transformation |
C0019652 | Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. | histone|Histones|Histone|histones | Histones |
C0019652 | Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. | histone|Histones|Histone|histones | Histones |
C0789995 | A filtering device designed to remove particles from air. | Air Cleaner Device|Air cleaner|Air Cleaner|room air cleaners|Air cleaner (physical object)|air cleaner|air cleaners | Air Cleaners - Device |
C0543467 | Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.) | surgical procedure|Surgical Interventions|Surgical Procedure|Operative Procedures|Operative procedure, NOS|operation|Type of Surgery|Surgical Procedure, Operative|Surgery, Operative|Procedure, Operative Surgical|surgical procedures|surgery procedure|Surgery|Procedures, Operative|operative procedures|Surgical Procedures|Surgical|Operation, NOS|operative surgery|Operative procedure|surgical treatments|Procedure, Operative|Operation|Surgical procedure (procedure)|operative procedure|Surgical procedure, NOS|surgery|Surgical Procedures, Operative|Surgical procedure|GENERIC OPERATIVE PROCEDURES|Operative Procedure|GENERAL OPERATIVE PROCEDURES|surgical treatment|Surgery (qualifier value)|Operative Surgical Procedures|operation (surgery)|surgeries|Operative Surgical Procedure|Surgical procedures|Procedures, Operative Surgical|Surgical (qualifier value)|Surgically | Operative Surgical Procedures |
C0179958 | null | CLEANERS, MEDICAL DEVICES|cleaners | Cleaning Device |
C0699680 | null | metrics|Metric|metric | Metric (substance) |
C0935616 | null | Chamber|chamber [body part]|chamber | Chamber (anatomical) |
C0260252 | null | emission spectroscopy | Emission spectroscopy |
C0231800 | Expelling modified air from the lungs; breathing out. | Expiration|exhaled|Exhalations|Expirations, Respiratory|Expiration (observable entity)|Respiratory Expirations|Expiratory|Expiring|Breathing out|Exhalation|Expired|expiration|Exhaling|Respiratory Expiration|Expiration, Respiratory|expiration body function|exhaling|exhalation|expiration (breathing)|Exhaling (observable entity) | Expiration, function |
C0004048 | Taking ambient air into the lungs; breathing in. | Inhaling|inspiratory|Inspiratory|Respiratory Inspiration|inhal|Inspired|inhaling|Inspiration|inspir|inhaled|inspiration|Inhalation|Inhale|inspirations|breathing|inspiration (breathing)|Inhaling (observable entity)|breathing inspiration|Inspiration (observable entity)|inhalations|inhalation|breathing in|Inhaled|Breathing in|Inspiration, Respiratory|respiratory aspiration|inspired|in breathing | Inspiration function |
C0221920 | null | Epidermo-|Epidermal|epidermal | Epidermal |
C0205112 | The lowest layer of a structure. | BASAL|basal|Basal|Basal (qualifier value) | Basal |
C0022567 | Epidermal cells which synthesize keratin and undergo characteristic changes as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell. | KERATINOCYTE|Keratinocyte|keratinocytes|Keratinized cell of epidermis|Keratinocyte (cell)|keratinocyte|Keratinocytes | keratinocyte |
C0597694 | widely used in research in developmental biology because of the size and robustness of the eggs and their amenability to surgical manipulation; used to study the expression and function of isolated foreign genes and RNAs injected into them. | null | Xenopus oocyte |
C0009196 | A fine channel that passes through the TEMPORAL BONE near the SCALA TYMPANI (the basilar turn of the cochlea). The cochlear aqueduct connects the PERILYMPH-filled bony labyrinth to the SUBARACHNOID SPACE. | Ducts, Perilymphatic|Perilymphatic Ducts|Structure of perilymphatic duct (body structure)|Structure of perilymphatic duct|Aqueducts, Cochlear|Perilymphatic Duct|Perilymphatic duct|Cochlear Aqueducts|Aqueduct, Cochlear|Duct, Perilymphatic|Cochlear Aqueduct | Structure of perilymphatic duct |
C0007603 | The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. | Cell membrane, NOS|Membrane, Plasma|Membranes, Cell|Plasma membrane|Cell membrane (cell structure)|Plasma Membranes|plasma membrane|Cytoplasmic membrane|Cytoplasmic Membrane|plasmalemma|Cytoplasmic Membranes|plasma membranes|cellular membrane|cell membrane|Membrane, Cytoplasmic|membranes plasma|cell membranes|Membrane, Cell|Membranes, Plasma|Cell membrane|cells membrane|membrane plasma|Membranes, Cytoplasmic|plasma membrane lipid bilayer|Plasma Membrane|Cellular membrane|cytoplasmic membrane|Cell Membrane|Cell Membranes|membrane cell|Cell membranes|Plasmalemma | Plasma membrane |
C0014239 | A system of cisternae in the CYTOPLASM of many cells. In places the endoplasmic reticulum is continuous with the plasma membrane (CELL MEMBRANE) or outer membrane of the nuclear envelope. If the outer surfaces of the endoplasmic reticulum membranes are coated with ribosomes, the endoplasmic reticulum is said to be rough-surfaced (ENDOPLASMIC RETICULUM, ROUGH); otherwise it is said to be smooth-surfaced (ENDOPLASMIC RETICULUM, SMOOTH). (King & Stansfield, A Dictionary of Genetics, 4th ed) | Ergastoplasm|Reticulum endoplasmicum|Endoplasmic Reticulum|endoplasmic reticulum (ER)|endoplasmic reticulum|ER|Reticulum, Endoplasmic|Reticulum cytoplasmaticum|Endoplasmic reticulum (cell structure)|Endoplasmic reticulum, NOS|Endoplasmic reticulum | Endoplasmic Reticulum |
C1154413 | Any process that mediates the transfer of information from one cell to another. This process includes signal transduction in the receiving cell and, where applicable, release of a ligand and any processes that actively facilitate its transport and presentation to the receiving cell. Examples include signaling via soluble ligands, via cell adhesion molecules and via gap junctions. [GOC:dos, GOC:mah] | intercellular communication|cell-cell signaling|Short-Range Multicellular Communication|cell-cell signalling|Intercellular Communication|cell-to-cell signaling|Cell to Cell Communication and Signaling|Cell-Cell Signaling | Intercellular Communication Process |
C0034538 | ELECTROMAGNETIC RADIATION or particle radiation (high energy ELEMENTARY PARTICLES) capable of directly or indirectly producing IONS in its passage through matter. The wavelengths of ionizing electromagnetic radiation are equal to or smaller than those of short (far) ultraviolet radiation and include gamma and X-rays. | Radiation, Ionizing|Radiations, Ionizing|ionizing radiation|Ionizing radiation|radiation ionize|electromagnetic ionising radiation|Radiation-Ionizing Total|Ionising radiation|Ionizing Radiation|ionising radiation|Ionizing radiation (physical force)|Ionizing electromagnetic radiation|Ionising electromagnetic radiation|Ionizing electromagnetic radiation (physical force)|Ionizing Radiations|ionized radiation | Ionizing radiation |
C0057673 | null | 4,4'-diacetyldiphenylurea 4,4'-bis(guanylhydrazone)|DDUG|4,4'-diacetylcarbanilide 4,4'-bis(amidinohydrazone) | diacetyldiphenylurea bisguanylhydrazone |
C0225336 | Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer. | Cell, Endothelial|endothelial cell|cell endothelial|Cells, Endothelial|cells endothelial|Endothelial Cell|Endotheliocyte|Endothelial Cells|Endothelial cells|endothelial cells|Endothelial cell|Endothelial cell (cell) | Endothelial Cells |
C0558024 | null | Functional behavioural assessment|Functional analysis|functional analysis|Functional behavioral assessment (procedure)|analysis functional | Functional behavioral assessment |
C0029418 | Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone. | Osteoblasts|Osteoblast (cell)|osteoblast|osteoblasts|cells osteoblasts|cells osteoblast|Osteoblast | Osteoblasts |
C0812437 | null | curtius syndrome|OCULODENTODIGITAL DYSPLASIA|Oculodentodigital Syndrome|Ectodermal dysplasia-ocular malformation syndrome (disorder)|ODD SYNDROME|Ectodermal dysplasia-ocular malformation syndrome|oculodentodigital syndrome|syndrome oculodentodigital|oculodentodigital dysplasia|Oculodentodigital syndrome|Curtius' syndrome I|Oculodentoosseous Dysplasia|Ectodermal dysplasia with ocular malformations syndrome|Oculo-Dento-Digital Dysplasia|Curtius' syndrome|ODD Syndrome|Osseous-Oculo-Dental Dysplasia|oculo dento digital syndrome|OCULODENTOOSSEOUS DYSPLASIA|Oculodentodigital Dysplasia|Oculodentodigital dysplasia|ODDD|ODOD|OCULODENTODIGITAL DYSPLASIA SYNDROME|Oculo-Dento-Osseous Dysplasia|Oculodentodigital syndrome (disorder) | Oculo-dento-digital syndrome |
C0023882 | A type of cerebral palsy characterized by spasticity and hypertonia of the lower extremities bilaterally, particularly the legs, hips, and pelvis; this is the most common (70%) form of cerebral palsy. | Spastic Diplegia|Spastic Diplegias|Spastic diplegia|little disease|PARALYSIS SPASTIC CONGENITAL|Diplegias, Spastic|Little's disease|diplegia spastic|Congenital spastic paralysis|Spastic diplegia syndrome|Spastic diplegia (disorder)|spastic infantile paralysis|Diplegia, Spastic|Little Disease|cerebral spastic infantile paralysis|Spastic infantile paralysis|spastic diplegia|Little's Disease|little's disease | Little's Disease |
C0016360 | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. | FLUOROURACIL|Fluorouracilo|5-fluorouracil|5fluorouracil|5-Fluoro-2,4(1H, 3H)-pyrimidinedione|5-Fluoracil|Fluorouracil (substance)|5-Fluorouracil|5-Fluoropyrimidine-2,4-dione|5-FU|5-fluoro-2,4(1H,3H)-pyrimidinedione|FU|2,4(1H,3H)-Pyrimidinedione, 5-fluoro-|Fluoruracil|5FU|5-fu|Fluorouracilum|Fluorouracil-containing product|5-Fluoro-2,4(1H,3H)-pyrimidinedione|2,4-dioxo-5-fluoropyrimidine|2,4-Dioxo-5-fluoropyrimidine|5 FU|fluorouracil|5 fluorouracil|5 fu|5Fluracil|Fluoro Uracil|Fluouracil|5-Fluracil|5 Fluorouracil|fluouracil|5-Fu|Fluorouracil|5 Fluorouracilum|Product containing fluorouracil (medicinal product) | fluorouracil |
C0016360 | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. | FLUOROURACIL|Fluorouracilo|5-fluorouracil|5fluorouracil|5-Fluoro-2,4(1H, 3H)-pyrimidinedione|5-Fluoracil|Fluorouracil (substance)|5-Fluorouracil|5-Fluoropyrimidine-2,4-dione|5-FU|5-fluoro-2,4(1H,3H)-pyrimidinedione|FU|2,4(1H,3H)-Pyrimidinedione, 5-fluoro-|Fluoruracil|5FU|5-fu|Fluorouracilum|Fluorouracil-containing product|5-Fluoro-2,4(1H,3H)-pyrimidinedione|2,4-dioxo-5-fluoropyrimidine|2,4-Dioxo-5-fluoropyrimidine|5 FU|fluorouracil|5 fluorouracil|5 fu|5Fluracil|Fluoro Uracil|Fluouracil|5-Fluracil|5 Fluorouracil|fluouracil|5-Fu|Fluorouracil|5 Fluorouracilum|Product containing fluorouracil (medicinal product) | fluorouracil |
C1167322 | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. [GOC:dos, GOC:go_curators] | integral component of membrane|integral to membrane|transmembrane | integral to membrane |
C0729502 | null | Chemotherapeutic agent|agents chemotherapeutic|Chemotherapeutic agent (product)|chemotherapeutic agent | Chemotherapeutic agent |
C0242643 | A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE). | p-gp|P Glycoprotein|p-glycoprotein|P-glycoprotein|Antigen, CD243|Multidrug Resistance Protein 1|PGY-1 Protein|MDR1 Protein|ABCB1 Protein|ATP Binding Cassette Transporter, Subfamily B, Member 1|PGY 1 Protein|CD243 Antigen|P-Glycoprotein|P glycoprotein|ATP-Binding Cassette, Sub-Family B, Member 1|glycoprotein p|ATP Binding Cassette Transporter, Sub-Family B, Member 1|p glycoprotein | P-Glycoprotein |
C0023005 | Recirculating, dendritic, antigen-presenting cells containing characteristic racket-shaped granules (Birbeck granules). They are found principally in the stratum spinosum of the EPIDERMIS and are rich in Class II MAJOR HISTOCOMPATIBILITY COMPLEX molecules. Langerhans cells were the first dendritic cell to be described and have been a model of study for other dendritic cells (DCs), especially other migrating DCs such as dermal DCs and INTERSTITIAL DENDRITIC CELLS. | cell langerhans|Langerhans' cell (cell)|Langerhans Cells|Dendritic Cells, Epidermal|Dendritic Cell, Epidermal|Epidermal Dendritic Cell|Cell, Epidermal Dendritic|Langerhans cell|Langerhans' cell|Langerhans cells|langerhans cell|cells langerhan|langerhan cell|Epidermal Dendritic Cells|langerhans cells|Cells, Epidermal Dendritic|Cells, Langerhans|cells langerhans|Langerhans Cell | Langerhans cell |
C0031307 | Cells that can carry out the process of PHAGOCYTOSIS. | Phagocytic cell (cell)|Phagocytes|phagocytes|Phagocytic Cells|cells phagocytic|Cells, Phagocytic|phagocytic cell|Phagocytic cell, NOS|amebocyte|Cell, Phagocytic|Phagocyte|Phagocytic cell|phagocyte|Phagocyte, NOS|Phagocytic Cell | Phagocytes |
C0043309 | Penetrating electromagnetic radiation emitted when the inner orbital electrons of an atom are excited and release radiant energy. X-ray wavelengths range from 1 pm to 10 nm. Hard X-rays are the higher energy, shorter wavelength X-rays. Soft x-rays or Grenz rays are less energetic and longer in wavelength. The short wavelength end of the X-ray spectrum overlaps the GAMMA RAYS wavelength range. The distinction between gamma rays and X-rays is based on their radiation source. | Roentgen Rays|x-ray|X-ray electromagnetic radiation|Xray|X-Radiation|Xrays|X-RAY|X-Radiations|Rays, Roentgen|x-rays|X-rays|X-ray electromagnetic radiation (physical force)|X ray|x rayed|x ray|X-radiation|X-ray|radiation x|xrays|xraying|X Rays|X-Ray|x rays|X Radiation|Radiation, X|x-radiation|Radiation, X-Rays|grenz ray|X-Rays|x raying|xray | Roentgen Rays |
C0178874 | A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a neoplasm. | tumor progression|Tumor progression|cancer progression|neoplasm progression|Tumor progression (finding)|neoplastic progression|Tumor Progression|Tumour progression | Tumor Progression |
C0020960 | Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. | Immune serums|immune sera|Immune Serums|Antisera|Product containing antiserum|Antiserum|Serums, Immune|Immune Sera|Therapeutic antiserum|DRUG ANTISERUMS|serum immune|antiserum|Antiserum product|Sera, Immune|immune serum|antisera|IMMUNE SERUMS|Antiserum, NOS|Product containing antiserum (product)|Antiserum (substance)|Therapeutic antiserum, NOS|Drug antiserum, NOS | Immune Sera |
C0030809 | An autoimmune blistering disorder. It is characterized by the presence of painful blisters and erosions in the skin and mucous membranes. | Pemphigus, vulgaris|PEMPHIGUS VULGARIS|pemphigus pv vulgaris|pemphigus vulgaris|Pemphigus Vulgaris|Pemphigus vulgaris|PV - Pemphigus vulgaris|Pemphigus vulgaris (disorder) | Pemphigus Vulgaris |
C0003242 | Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. | Antibody, Anti-Idiotypic|Antibodies, Anti-Idiotype|antiidiotype antibody|antiglobulin|Anti-Anti-Idiotype|antibodies anti|Antibodies, Anti-Idiotypic|anti idiotypic antibodies|anti antibody|anti idiotype antibody|Antibodies, Anti Idiotypic|Anti Idiotype Antibodies|Anti-Idiotype Antibody|Anti-Idiotypic Antibodies|antiglobulins|Anti-idiotypic antibodies|Anti-Idiotype Antibodies | Antibodies, Anti-Idiotypic |
C0000887 | Separation of the prickle cells of the stratum spinosum of the epidermis, resulting in atrophy of the prickle cell layer. It is seen in diseases such as pemphigus vulgaris (see PEMPHIGUS) and DARIER DISEASE. | Acantholyses|Acantholysis|acantholysis|Acantholysis (morphologic abnormality) | Acantholysis |
C0003242 | Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. | Antibody, Anti-Idiotypic|Antibodies, Anti-Idiotype|antiidiotype antibody|antiglobulin|Anti-Anti-Idiotype|antibodies anti|Antibodies, Anti-Idiotypic|anti idiotypic antibodies|anti antibody|anti idiotype antibody|Antibodies, Anti Idiotypic|Anti Idiotype Antibodies|Anti-Idiotype Antibody|Anti-Idiotypic Antibodies|antiglobulins|Anti-idiotypic antibodies|Anti-Idiotype Antibodies | Antibodies, Anti-Idiotypic |
C0014876 | The muscular membranous segment between the PHARYNX and the STOMACH in the UPPER GASTROINTESTINAL TRACT. | Gullet|Esophageal structure|gullet|Esophagus, NOS|esophagus|Oesophagus|Oesophagus, NOS|Oesophageal structure|Esophageal structure (body structure)|Gastrointestinal Tract, Esophagus|Esophagus|oesophagus|ESOPHAGUS | Esophagus |
C0582263 | Proteins whose major function is to give shape and support to tissues, cells, and subcellular structures. | Structural Protein|Structural protein (substance)|structural proteins | Structural protein |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.